Researchers have identified serine threonine kinase 10 as a key regulator of platelet function, haemostasis and ...
News-Medical.Net on MSN
Two isoforms of a cellular energy sensor play distinct, opposing roles in Alzheimer's disease
A comprehensive mini-review published today after peer review in Brain Medicine by Dr. Tao Ma and colleagues at Wake Forest ...
USFDA has cleared the world’s first oral therapy for the condition, a development that health experts say could transform ...
KAIST Demonstrates Potential to Predict Drug Side Effects and Acute Kidney Injury Using a Small Chip
Rhabdomyolysis is a condition in which muscle damage—often caused by drug intake—can lead to impaired kidney function and ...
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics ...
The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...
Agios Pharma's shares soar 16% after FDA expands approval for its blood disorder drug, Aqvesme, set for late next month.
Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one ...
Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.
The combination of ribociclib and letrozole achieved a 30.6% objective response rate and 84% clinical benefit rate in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback